U.S. Retail Distributors Stock News

Atomera (ATOM) is back on investors’ radar after reporting fourth quarter and full year 2025 results that highlight very small current sales, continued losses, and ongoing investment in its Mears Silicon Technology platform. See our latest analysis for Atomera. The latest earnings release and technical updates landed alongside a sharp shift in sentiment, with a 46.17% 1 day share price return and a 142.80% year to date share price return contrasting with a 5 year total shareholder return...

Occidental Petroleum agreed to sell its OxyChem business for $9.7 billion, marking a major reshaping of its portfolio. The transaction is expected to affect the company’s balance sheet, debt mix, and capital return plans once completed. Investors are watching how proceeds from the sale could influence future buybacks, dividends, and overall financial flexibility. For investors tracking NYSE:OXY, this move comes at a time when the shares trade around $45.94 and the longer-term record has...

In February 2026, State Street Corporation announced that Mariner will adopt Charles River’s Wealth Management Solution to support its goal of scaling from more than 2,080 advisors toward 5,000 while centralizing portfolio management, trading, data integration, and advisor workflows. State Street Investment Management also launched the actively managed State Street Prime Money Market ETF (ticker: MMK), a low-cost prime cash vehicle drawing on its cash team’s US$599.55 billion in assets...

Why Kulicke and Soffa Industries (KLIC) Is On Investors’ Radar Kulicke and Soffa Industries (KLIC) has drawn fresh attention after a strong past 3 months for the stock, with recent trading around $71.77 prompting investors to reassess its valuation and fundamentals. See our latest analysis for Kulicke and Soffa Industries. While the share price is around $71.77 after a 24.71% 1 month share price return and 103.37% 3 month share price return, the 72.18% 1 year total shareholder return suggests...

Pilgrim's Pride (PPC) is back in focus after reporting fourth quarter 2025 earnings, with higher sales and softer margins, plus a sizable 2026 capex plan aimed at prepared foods capacity and operational efficiencies. See our latest analysis for Pilgrim's Pride. The latest earnings release and 2026 capex plan come after a period of firm momentum in the shares, with a 30 day share price return of 5.10% and a 90 day share price return of 15.61%. This is the case even though the 1 year total...

Why this leadership change at T1 Energy (TE) is on investors’ radar T1 Energy (TE) just made an abrupt change in a key finance role, with the immediate departure of Chief Accounting Officer and Corporate Controller Denise Cruz and the same-day appointment of Tom Mahrer. Because this position oversees accounting policy and financial reporting, any sudden shift can draw investor focus to how the company’s numbers are produced, audited, and communicated to the market. See our latest analysis for...

Short interest in MARA Holdings (NasdaqCM:MARA) has recently moved sharply higher, now sitting well above levels seen in many peers. Analysts have turned more cautious on the stock, citing sector risks and increased insider selling activity. The shift in positioning comes even as some earnings estimates for MARA Holdings have been revised upward. MARA Holdings, listed on NasdaqCM under the ticker MARA, has attracted fresh attention as investor positioning has turned more bearish. The...

Twist Bioscience (NasdaqGS:TWST) agreed to license Invenra’s B-Body bispecific antibody platform on a co exclusive basis, while also taking an equity stake and a board seat in Invenra. The company also introduced new advanced library preparation kits aimed at next generation sequencing and clinical research customers. For you as an investor, these moves sit at the intersection of antibody discovery and genomics tools, which is where Twist Bioscience has been building its business. The tie...

Atlassian (NasdaqGS:TEAM) highlighted rapid uptake of its Rovo AI platform in the latest quarter, pointing to expanding use across enterprise customers. The company reported new milestones in cloud revenue alongside this AI adoption, underscoring the role of cloud products in its business mix. Management raised full year guidance following strong quarterly results, signaling that recent operating trends are influencing its outlook for the rest of the year. For investors watching...

Why CRH (NYSE:CRH) is in focus today CRH (NYSE:CRH) heads into its quarterly earnings announcement on February 18, 2026, with investors watching both the profit update and any guidance, while its ongoing $300 million buyback continues through recent 29,600-share repurchases. See our latest analysis for CRH. CRH’s 1-day share price return of a 3.14% decline and 7-day share price return of a 5.52% decline contrast with a stronger 90-day share price return of 10.78% and a 3-year total...

In February 2026, Truist Financial Corporation announced its first open banking integration, using Mastercard’s open finance technology to give consumer and small business clients secure, API-based connections to fintech apps with tokenized data access and centralized control. This move highlights how Truist is using partnership-driven technology to enhance client data security and customization while expanding its role in the open finance ecosystem. We’ll now examine how Truist’s...

Harvard Management Company shifts a significant portion of its cryptocurrency exposure from BlackRock’s iShares Bitcoin Trust to a new position in the iShares Ethereum Trust. BlackRock (NYSE:BLK) prepares to launch ETHB, an Ethereum ETF that will be the first U.S. listed product to offer staking rewards within a regulated ETF structure. The moves point to growing institutional interest in diversified digital asset exposure beyond Bitcoin, using BlackRock’s regulated vehicles. For you as an...

What the new credit facility and 2026 outlook mean for Oscar Health Oscar Health (OSCR) just paired a new US$475 million revolving credit facility with fresh 2026 guidance and full year 2025 results. Together, these provide a clearer view of its balance sheet and earnings ambitions. See our latest analysis for Oscar Health. The new credit facility and 2026 outlook arrive after a mixed year in the market, with a 7 day share price return of 3.96% but a 30 day share price return decline of...

Stock performance snapshot and recent context Dauch (DCH) has drawn attention after a period of mixed share performance, with a small 1 day gain of 0.41% contrasting with a roughly 14% decline over the past week. Over the past month the stock shows a decline of about 5%, while the past 3 months are positive at roughly 17%. Year to date, Dauch is up about 12%, with a 1 year total return of around 26%. See our latest analysis for Dauch. The latest 7 day share price return of around 14% decline...

Why Exact Sciences (EXAS) is on investors’ radar Exact Sciences (EXAS) has drawn attention after a period of strong 1 year total return of 108.16% and past 3 months return of 19.88%, prompting closer scrutiny of its current valuation. See our latest analysis for Exact Sciences. At a share price of US$103.31, Exact Sciences has seen a strong 1 year total shareholder return of 108.16%, while its 90 day share price return of 19.88% suggests momentum has recently picked up after a more muted...

If you are wondering whether Tronox Holdings at around US$7.60 is a bargain or a value trap, looking closely at how the market is pricing the business is a good place to start. The share price has been volatile recently, with a 32.9% return over the last 30 days, a 78.0% return year to date, but only a 1.7% return over the past year and longer term declines of 41.8% over three years and 54.2% over five years. These swings have put Tronox back on the radar for investors comparing short term...

What recent returns are telling investors about Asana (ASAN) Asana (ASAN) has been on many watchlists after a stretch of weak share performance, with the stock down over the past month, past 3 months, year to date, and over the past year. Those returns, including a 2.6% decline over the past day and double digit drops across recent periods, are prompting investors to look more closely at how Asana’s business metrics line up with its current share price. See our latest analysis for Asana. At a...

Dell Technologies expanded its partnership with McLaren Racing to supply advanced AI infrastructure and data solutions for Formula 1 operations. The collaboration focuses on AI powered servers, simulation platforms, and data tools to support race strategy, car development, and real time decision making. For investors watching NYSE:DELL, this update highlights how Dell Technologies is positioning its AI and data stack in a demanding, mission critical setting. The company’s shares most...

Citigroup analyst Scott Gruber recently reiterated a Neutral rating on Borr Drilling and raised its price target, while the company released its Q4 2025 earnings today after previously signaling an expected earnings per share loss of $0.03. These developments highlight how analysts are closely tracking Borr Drilling’s contracting progress and financial outlook as they reassess expectations for its offshore drilling operations across multiple regions. We’ll now examine how the upcoming...

BigBear.ai Holdings (NYSE:BBAI) completed its acquisition of Ask Sage, adding new AI capabilities to its platform. The company also carried out a significant debt reduction by converting a portion of its outstanding notes into equity. Together, these moves reshape BigBear.ai’s capital structure and product offering in the AI and data analytics space. BigBear.ai focuses on AI driven decision intelligence and data analytics, serving both government and commercial customers. The Ask Sage...

Boston Scientific (NYSE:BSX) has started the OPTION-EMEA clinical trial in real world hospital settings across Europe. The study evaluates the combined use of two cardiac devices for patients with atrial fibrillation and stroke prevention. The trial is designed to assess safety and potential benefits of this combined therapy approach in routine clinical practice. For investors watching NYSE:BSX, this new trial comes as the shares trade at $76.29. The stock is up 65.0% over the past 3 years...

Earnings, guidance and buyback put AptarGroup in focus AptarGroup (ATR) just released fourth quarter and full year 2025 results, issued fresh first quarter 2026 earnings guidance and unveiled a new US$600 million share repurchase program that together give investors several moving pieces to assess. See our latest analysis for AptarGroup. At a share price of US$141.65, AptarGroup has seen a 13.58% 1 month share price return and a 20.04% 3 month share price return. Its 1 year total shareholder...

Allegiant Travel Company (NasdaqGS:ALGT) has launched a themed "Destination Dollywood" flight experience in partnership with Dollywood Parks & Resorts. The offering combines tailored in flight entertainment with bundled travel and resort packages tied to the Dollywood brand. The collaboration focuses on leisure travelers seeking packaged experiences that connect air travel with on the ground attractions. For Allegiant Travel, which focuses on leisure oriented, low cost flying, this type of...

Euronet Worldwide recently reported past fourth-quarter 2025 results, with sales rising to US$1,108.7 million and net income to US$51.5 million, and confirmed it has completed a multi-year share repurchase program totaling 15,673,988 shares for US$1.48 billions. Despite only modest full-year net income growth to US$309.5 million, the company’s diluted EPS increased to US$6.84, helped by substantial share buybacks that reduced the share count by over one-third. Next, we will examine how...